SillaJen, Inc.

A215600

KR7215600008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
4,525 ^KRW	-0.22%		+0.67%	-24.96%

Apr. 22	OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	CI
Mar. 27	SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	CI

SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index

September 21, 2020 at 12:00 am EDT

SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index (USD)

Latest news about SillaJen, Inc.

OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	Apr. 22	CI
SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	Mar. 27	CI
SillaJen to Raise 129.4 Billion Won via Shares Issuance	Mar. 25	MT
SillaJen, Inc.(KOSDAQ:A215600) added to S&P Global BMI Index	23-09-18	CI
Switzerland's Basilea Pharmaceutica Secures $4 Million Milestone Payment for Oncology Asset	22-12-19	MT
SillaJen Resumes Trading on Kosdaq	22-10-13	MT
SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug	22-09-21	MT
Kosdaq Delists Biotechnology Company SillaJen	22-01-19	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	21-11-24	CI
SillaJen, Inc. announced that it has received KRW 40 billion in funding	21-08-30	CI
SillaJen, Inc. announced that it has received KRW 60 billion in funding from M2N Co.,Ltd	21-07-14	CI
SillaJen, Inc. announced that it expects to receive KRW 40 billion in funding	21-07-13	CI
SillaJen, Inc. announced that it expects to receive KRW 60 billion in funding from M2N Co.,Ltd	21-05-30	CI
M2N Co.,Ltd signed LOI to acquire SillaJen, Inc..	21-04-20	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from S&P Global BMI Index	20-09-21	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index	20-09-21	CI
SillaJen, Inc. announced that it has received KRW 20 billion in funding	20-04-23	CI
SillaJen, Inc. announced that it expects to receive KRW 20 billion in funding	20-04-22	CI
Sillajen Announces Conclusions from Interim Futility Analysis of Phase 3 PHOCUS Trial in HCC	19-08-02	CI
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)	19-06-06	CI
SillaJen, Inc. announced that it has received KRW 110 billion in funding	19-03-20	CI
SillaJen, Inc. announced that it expects to receive KRW 110 billion in funding	19-03-18	CI
SillaJen, Inc. Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab	18-06-20	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	18-03-19	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	18-03-19	CI

SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Sector

Biotechnology & Medical Research

Calendar

2024-05-12 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SILLAJEN, INC.	-24.96%	338M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B